Targeting a life-changing impact for people living with EBS

Epidermolysis bullosa simplex (EBS) is the most common form of epidermolysis bullosa (EB), an uncommon dermatologic condition. For many patients, EBS can be debilitating and there are currently no treatment options available but only supportive care that includes wound care and use of bandages as well as pain management. But researchers are learning more about the underlying genetic cause of this rare disease every day.

Diacerein 1% ointment (CCP-020) is a potentially disease-modifying investigational drug that may block an important inflammatory signaling pathway associated with EBS. Its efficacy and safety is now being evaluated in the DELIVERS clinical trial as a potential treatment for EBS.